Cargando…

Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma(†)

OBJECTIVE: This single-arm, open-label, Phase II study evaluated the efficacy and safety of single-agent bevacizumab, a monoclonal antibody against vascular endothelial growth factor, in Japanese patients with recurrent malignant glioma. METHODS: Patients with histologically confirmed, measurable gl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagane, Motoo, Nishikawa, Ryo, Narita, Yoshitaka, Kobayashi, Hiroyuki, Takano, Shingo, Shinoura, Nobusada, Aoki, Tomokazu, Sugiyama, Kazuhiko, Kuratsu, Junichi, Muragaki, Yoshihiro, Sawamura, Yutaka, Matsutani, Masao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2012
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448378/ https://www.ncbi.nlm.nih.gov/pubmed/22844129 http://dx.doi.org/10.1093/jjco/hys121

Ejemplares similares

Bevacizumab for Glioblastoma—A Promising Drug or Not?
por: Nagane, Motoo, et al.
Publicado: (2013)

NQPC-01 CURRENT STATUS AND PROBLEMS OF ADVANCE CARE PLANNING AND PALLIATIVE CARE FOR MALIGNANT BRAIN TUMOR
por: Aoki, Tomokazu, et al.
Publicado: (2019)

Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan
por: AOKI, Tomokazu, et al.
Publicado: (2020)

Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study
por: Motoo, Nagane, et al.
Publicado: (2019)

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
por: Nagane, Motoo, et al.
Publicado: (2022)

Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study
por: Aoki, Tomokazu, et al.
Publicado: (2021)

ML-05 One-year follow-up data of phase I/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
por: Mishima, Kazuhiko, et al.
Publicado: (2020)

Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib
por: Arakawa, Yoshiki, et al.
Publicado: (2023)

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
por: Narita, Yoshitaka, et al.
Publicado: (2020)

JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
por: Wakabayashi, Toshihiko, et al.
Publicado: (2018)

Toxicity and Outcome of Radiotherapy with Concomitant and Adjuvant Temozolomide in Elderly Patients with Glioblastoma: A Retrospective Study
por: SAITO, Kuniaki, et al.
Publicado: (2014)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial
por: Narita, Yoshitaka, et al.
Publicado: (2021)

Transduction of a Fiber‐mutant Adenovirus for the HSVtk Gene Highly Augments the Cytopathic Effect towards Gliomas
por: Shinoura, Nobusada, et al.
Publicado: (2000)

Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study
por: Nishikawa, Ryo, et al.
Publicado: (2023)

Adenovirus‐mediated Transfer of Fas Ligand Gene Augments Radiation‐induced Apoptosis in U‐373MG Glioma Cells
por: Shinoura, Nobusada, et al.
Publicado: (2000)

Co‐transduction of Apaf‐1 and Caspase‐9 Augments Etoposide‐induced Apoptosis in U‐373MG Glioma Cells
por: Shinoura, Nobusada, et al.
Publicado: (2001)

Distinct molecular profile of diffuse cerebellar gliomas
por: Nomura, Masashi, et al.
Publicado: (2017)

Dissociation of the subjective and objective bodies: Out‐of‐body experiences following the development of a posterior cingulate lesion
por: Hiromitsu, Kentaro, et al.
Publicado: (2019)

GEN-1 ORIGINALLY DEVELOPED TUMOR SAMPLER TO REVEAL INTRATUMORAL HETEROGENEITY IN BRAIN TUMORS
por: Otani, Ryohei, et al.
Publicado: (2022)

A Multicenter Phase I/II Study of the BCNU Implant (Gliadel (®) Wafer) for Japanese Patients with Malignant Gliomas
por: AOKI, Tomokazu, et al.
Publicado: (2014)

DNA demethylation is associated with malignant progression of lower-grade gliomas
por: Nomura, Masashi, et al.
Publicado: (2019)

GCT-15. INTEGRATED CLINICAL, HISTOPATHOLOGICAL, AND MOLECULAR DATA ANALYSIS OF 190 CENTRAL NERVOUS SYSTEM GERM CELL TUMORS FROM THE IGCT CONSORTIUM
por: Takami, Hirokazu, et al.
Publicado: (2020)

Publisher Correction: DNA demethylation is associated with malignant progression of lower-grade gliomas
por: Nomura, Masashi, et al.
Publicado: (2019)

Genetic Characteristics of Mismatch Repair-deficient Glioblastoma
por: KAWAGUCHI, Kei, et al.
Publicado: (2021)

ACT-14 A FIRST-IN-HUMAN STUDY OF MUTANT IDH1 INHIBITOR DS-1001B IN PATIENTS WITH RECURRENT GLIOMAS
por: Arakawa, Yoshiki, et al.
Publicado: (2019)

A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis(†)
por: Furuse, Motomasa, et al.
Publicado: (2016)

MPC-08 CLINICOPATHOLOGICAL ANALYSIS OF 12P GAIN IN INTRACRANIAL GERM CELL TUMORS
por: Satomi, Kaishi, et al.
Publicado: (2019)

A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer
por: Sugiyama, Toru, et al.
Publicado: (2017)

GCT-43. GAIN OF SHORT ARM OF CHROMOSOME 12 IS A MOLECULAR MARKER TO PREDICT PROGNOSIS AND REPRESENTS AN EARLY EVENT IN TUMORIGENESIS IN INTRACRANIAL GERM CELL TUMORS
por: Satomi, Kaishi, et al.
Publicado: (2020)

Adenovirus‐mediated Gene Transduction of IkB or IkB Plus Bax Gene Drastically Enhances Tumor Necrosis Factor (TNF)‐induced Apoptosis in Human Gliomas
por: Shinoura, Nobusada, et al.
Publicado: (2000)

Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies
por: Ohno, Makoto, et al.
Publicado: (2022)

COT-17 EFFECT OF BEVACIZUMAB AGAINST CYSTIC COMPONENT OF PRIMARY/METASTATIC BRAIN TUMORS
por: Yamasaki, Fumiyuki, et al.
Publicado: (2019)

Dose-dense Temozolomide: Is It Still Promising?
por: NAGANE, Motoo
Publicado: (2015)

SS-1 Therapeutic challenges for glioblastoma: Temozolomide and its issues?
por: Nagane, Motoo
Publicado: (2020)

IL-4 CHALLENGES FOR MANAGEMENT OF PRIMARY CNS LYMPHOMA
por: Nagane, Motoo
Publicado: (2022)

GCT-52. TRANSCRIPTOME OF CENTRAL NERVOUS SYSTEM GERM CELL TUMOR REVEALS ITS PATHOGENESIS AND CONTRASTS WITH TESTICULAR COUNTERPARTS IN INTEGRATED OMICS ANALYSIS
por: Takami, Hirokazu, et al.
Publicado: (2020)

Biased Recognition of Surprised Facial Expressions Following Awake Craniotomy of a Right Temporal Lobe Tumor
por: Midorikawa, Akira, et al.
Publicado: (2019)

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
por: Natsume, Atsushi, et al.
Publicado: (2022)

Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial
por: Takano, Shingo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tqhrt4lnginvsp7m0c6lmrli87